A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
NCT ID: NCT06004050
Last Updated: 2025-09-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
362 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-09-05
Study Completion Date
2025-09-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema (CHE).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
NCT04871711
Chronic Hand Eczema
COMPLETED
PHASE3
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
NCT05486117
Chronic Hand Eczema
COMPLETED
PHASE1
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
NCT03683719
Chronic Hand Eczema
COMPLETED
PHASE2
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
NCT04872101
Chronic Hand Eczema
COMPLETED
PHASE3
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
NCT05355818
Chronic Hand Eczema
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The trial comprises of a 16-week double-blind, treatment period, followed by an open label treatment period of 36 weeks. In the double-blind treatment period two thirds of participants will be randomly assigned to receive delgocitinib and one third will receive placebo/vehicle. In the double-blind treatment period, participants will use delgocitinib twice a day. In the open label period, participants will only use delgocitinib when needed (if their CHE flares up). Some participants will also give blood samples at the start of the trial for pharmacokinetic measurements. Participants will visit the clinic every 4 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Hand Eczema
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Double-Blind Period: Twice-Daily Delgocitinib Cream
20 mg/g twice daily
Group Type
EXPERIMENTAL
Delgocitinib
Intervention Type
DRUG
Topical administration
Double-Blind Period: Twice-Daily Vehicle Cream
20 mg/g twice daily
Group Type
PLACEBO_COMPARATOR
Vehicle cream
Intervention Type
OTHER
Topical administration
Open Label Period: Twice-Daily Delgocitinib
20 mg/g twice daily
Group Type
EXPERIMENTAL
Delgocitinib
Intervention Type
DRUG
Topical administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Delgocitinib
Topical administration
Intervention Type
DRUG
Vehicle cream
Topical administration
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age 18 years or above at screening for adult participants and age 12-17 years at screening and baseline for adolescent participants.
2. Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months. Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4).
3. HESD itch score (weekly average) of ≥4 points at baseline. The baseline weekly average will be calculated from daily assessments of itch severity during the 7 days immediately preceding the baseline visit (Day -7 to Day -1). A minimum of 4 itch scores out of the 7 days is required to calculate the baseline average score.
4. Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
* Inadequate response is defined as a history of failure to achieve and maintain a low disease activity state (comparable to an IGACHE score of ≤2) despite treatment with a daily regimen of TCS of class III-IV (potent to very potent), applied for at least 28 days or for the maximum duration recommended by the product prescribing information, whichever is shorter.
* Important side effects or safety risks are those that outweigh the potential treatment benefits and include intolerance to treatment, hypersensitivity reactions, and significant skin atrophy as assessed by the physician.
5. Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
6. A woman of childbearing potential (WOCBP) must use an acceptable method of birth control throughout the trial up until the last application of investigational medicinal product (IMP).
2. Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months. Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4).
3. HESD itch score (weekly average) of ≥4 points at baseline. The baseline weekly average will be calculated from daily assessments of itch severity during the 7 days immediately preceding the baseline visit (Day -7 to Day -1). A minimum of 4 itch scores out of the 7 days is required to calculate the baseline average score.
4. Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
* Inadequate response is defined as a history of failure to achieve and maintain a low disease activity state (comparable to an IGACHE score of ≤2) despite treatment with a daily regimen of TCS of class III-IV (potent to very potent), applied for at least 28 days or for the maximum duration recommended by the product prescribing information, whichever is shorter.
* Important side effects or safety risks are those that outweigh the potential treatment benefits and include intolerance to treatment, hypersensitivity reactions, and significant skin atrophy as assessed by the physician.
5. Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
6. A woman of childbearing potential (WOCBP) must use an acceptable method of birth control throughout the trial up until the last application of investigational medicinal product (IMP).
Exclusion Criteria
1. Active atopic dermatitis (AD) requiring medical treatment in regions other than the hands and feet.
2. Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
3. Clinically significant infection (e.g. impetiginized hand eczema) on the hands.
4. Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the investigational medicinal product (IMP), or reduce the participant's ability to participate in the trial. Clinically significant infections are defined as:
* A systemic infection.
* A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
5. History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
6. History of cancer:
* Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to screening.
* Participants who have had other malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.
7. Any disorder which is not stable and could:
* Affect the safety of the participant throughout the trial.
* Impede the participant's ability to complete the trial. Examples include but are not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, immunological, and psychiatric disorders, and major physical impairment.
8. Any abnormal finding which may:
* Put the participant at risk because of their participation in the trial.
* Influence the participant's ability to complete the trial. The abnormal finding must be clinically significant and observed during the screening period. Examples include abnormal findings in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis.
9. Positive hepatitis B surface antigen or hepatitis C virus antibody serology at screening.
10. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0×ULN at screening.
11. Known or suspected hypersensitivity to any component(s) of the IMP.
12. Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), traditional Chinese medicines (TCMs) (including herbals), or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
13. Use of tanning beds, phototherapy (e.g. UVB, UVA1, PUVA), or bleach baths on the handswithin 28 days prior to baseline.
14. Previous or current treatment with Janus Kinase (JAK) inhibitors (including delgocitinib/LEO 124249),systemic or topical.
15. Cutaneously applied treatment with immunomodulators (e.g. PDE-4 inhibitors, pimecrolimus, tacrolimus), TCMs (including herbals), or TCS on the hands within 14 days prior to baseline.
16. Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
17. Other transdermal or cutaneously applied therapy on the hands (except for the use of participant's own emollients) within 7 days prior to baseline.
18. Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
19. Treatment with any marketed biological therapy or investigational biologic agents (including immunoglobulin, anti-IgE, and dupilumab):
• Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
• Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
20. Treatment with any non-marketed drug substance (that is, an agent that has not yet been made available for clinical use following registration) within the last 28 days prior to baseline or 5 half-lives, whichever is longer.
21. Major surgery within 8 weeks prior to screening, or planned in-patient surgery or hospitalization during the trial period.
22. Current participation in any other interventional clinical trial.
23. Previously randomized in this clinical trial.
24. Concurrent skin diseases on the hands, e.g. tinea manuum.
25. Active psoriasis on any part of the body.
26. Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.
27. Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.
28. Participants who are legally institutionalized.
29. Women who are pregnant or lactating.
2. Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
3. Clinically significant infection (e.g. impetiginized hand eczema) on the hands.
4. Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the investigational medicinal product (IMP), or reduce the participant's ability to participate in the trial. Clinically significant infections are defined as:
* A systemic infection.
* A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
5. History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
6. History of cancer:
* Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to screening.
* Participants who have had other malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.
7. Any disorder which is not stable and could:
* Affect the safety of the participant throughout the trial.
* Impede the participant's ability to complete the trial. Examples include but are not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, immunological, and psychiatric disorders, and major physical impairment.
8. Any abnormal finding which may:
* Put the participant at risk because of their participation in the trial.
* Influence the participant's ability to complete the trial. The abnormal finding must be clinically significant and observed during the screening period. Examples include abnormal findings in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis.
9. Positive hepatitis B surface antigen or hepatitis C virus antibody serology at screening.
10. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0×ULN at screening.
11. Known or suspected hypersensitivity to any component(s) of the IMP.
12. Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), immunomodulating drugs, retinoids (e.g. alitretinoin), traditional Chinese medicines (TCMs) (including herbals), or corticosteroids within 28 days prior to baseline (steroid eyedrops and inhaled or intranasal steroids corresponding to up to 1 mg prednisolone for allergic conjunctivitis, asthma, or rhinitis are allowed).
13. Use of tanning beds, phototherapy (e.g. UVB, UVA1, PUVA), or bleach baths on the handswithin 28 days prior to baseline.
14. Previous or current treatment with Janus Kinase (JAK) inhibitors (including delgocitinib/LEO 124249),systemic or topical.
15. Cutaneously applied treatment with immunomodulators (e.g. PDE-4 inhibitors, pimecrolimus, tacrolimus), TCMs (including herbals), or TCS on the hands within 14 days prior to baseline.
16. Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
17. Other transdermal or cutaneously applied therapy on the hands (except for the use of participant's own emollients) within 7 days prior to baseline.
18. Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
19. Treatment with any marketed biological therapy or investigational biologic agents (including immunoglobulin, anti-IgE, and dupilumab):
• Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
• Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
20. Treatment with any non-marketed drug substance (that is, an agent that has not yet been made available for clinical use following registration) within the last 28 days prior to baseline or 5 half-lives, whichever is longer.
21. Major surgery within 8 weeks prior to screening, or planned in-patient surgery or hospitalization during the trial period.
22. Current participation in any other interventional clinical trial.
23. Previously randomized in this clinical trial.
24. Concurrent skin diseases on the hands, e.g. tinea manuum.
25. Active psoriasis on any part of the body.
26. Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.
27. Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.
28. Participants who are legally institutionalized.
29. Women who are pregnant or lactating.
Minimum Eligible Age
12 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Expert
Role: STUDY_DIRECTOR
LEO Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LEO Pharma Investigational Site
Beijing, , China
Site Status
LEO Pharma Investigational Site
Beijing, , China
Site Status
LEO Pharma Investigational Site
Beijing, , China
Site Status
LEO Pharma Investigational Site
Beijing, , China
Site Status
LEO Pharma Investigational Site
Changchun, , China
Site Status
LEO Pharma Investigational Site
Changsha, , China
Site Status
LEO Pharma Investigational Site
Changsha, , China
Site Status
LEO Pharma Investigational Site
Changzhou, , China
Site Status
LEO Pharma Investigational Site
Chengdu, , China
Site Status
LEO Pharma Investigational Site
Chengdu, , China
Site Status
LEO Pharma Investigational Site
Fuzhou, , China
Site Status
LEO Pharma Investigational Site
Guangzhou, , China
Site Status
LEO Pharma Investigational Site
Guangzhou, , China
Site Status
LEO Pharma Investigational Site
Guiyang, , China
Site Status
LEO Pharma Investigational Site
Hangzhou, , China
Site Status
LEO Pharma Investigational Site
Hangzhou, , China
Site Status
LEO Pharma Investigational Site
Hangzhou, , China
Site Status
LEO Pharma Investigational Site
Hefei, , China
Site Status
LEO Pharma Investigational Site
Nanchang, , China
Site Status
LEO Pharma Investigational Site
Nanjing, , China
Site Status
LEO Pharma Investigational Site
Nanyang, , China
Site Status
LEO Pharma Investigational Site
Shanghai, , China
Site Status
LEO Pharma Investigational Site
Shenyang, , China
Site Status
LEO Pharma Investigational Site
Shenzhen, , China
Site Status
LEO Pharma Investigational Site
Shenzhen, , China
Site Status
LEO Pharma Investigational Site
Shenzhen, , China
Site Status
LEO Pharma Investigational Site
Shenzhen, , China
Site Status
LEO Pharma Investigational Site
Shijiazhuang, , China
Site Status
LEO Pharma Investigational Site
Wenzhou, , China
Site Status
LEO Pharma Investigational Site
Wuhan, , China
Site Status
LEO Pharma Investigational Site
Wuhan, , China
Site Status
LEO Pharma Investigational Site
Wuhan, , China
Site Status
LEO Pharma Investigational Site
Wuxi, , China
Site Status
LEO Pharma Investigational Site
Xianyang, , China
Site Status
LEO Pharma Investigational Site
Yinchuan, , China
Site Status
LEO Pharma Investigational Site
Yiwu, , China
Site Status
LEO Pharma Investigational Site
Zhenjiang, , China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LP0133-2283
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
NCT05259722
COMPLETED
PHASE3
Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
NCT03826901
COMPLETED
PHASE1
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
NCT03725722
COMPLETED
PHASE2
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
NCT04949841
COMPLETED
PHASE3
A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis
NCT07185282
COMPLETED
PHASE3
A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT04162899
COMPLETED
PHASE2
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
NCT06931990
NOT_YET_RECRUITING
PHASE1/PHASE2
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
NCT04717310
UNKNOWN
PHASE2/PHASE3
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993
RECRUITING
PHASE2
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
NCT07182864
COMPLETED
PHASE1/PHASE2
A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis
NCT06587685
RECRUITING
PHASE3
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07054736
NOT_YET_RECRUITING
PHASE2
Apremilast and Moderate to Severe Chronic Hand Dermatitis
NCT03741933
WITHDRAWN
PHASE4
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT06012812
ENROLLING_BY_INVITATION
PHASE2
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
NCT07211542
RECRUITING
PHASE2
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
NCT07000630
NOT_YET_RECRUITING
NA
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
NCT03903822
COMPLETED
PHASE2
Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
NCT02664805
COMPLETED
PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis
NCT06035354
COMPLETED
PHASE1/PHASE2
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
NCT03912259
COMPLETED
PHASE3
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
NCT06026891
RECRUITING
PHASE3
A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis
NCT07158151
RECRUITING
PHASE2
Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream
NCT01850849
COMPLETED
PHASE1
Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis
NCT00919763
COMPLETED
PHASE2
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
NCT07216027
RECRUITING
PHASE2